Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

CSL Says Many Issues Raised in 2010, 2011 FDA Audits Addressed

Sept. 29 (Bloomberg) -- CSL Ltd., the world’s second-biggest maker of blood-derived therapies, says many of the concerns raised in audits conducted by the U.S. Food and Drug Administration in 2010 and 2011 have been addressed.

“These aren’t new issues,” spokeswoman Sharon McHale said today after the Australian newspaper published a story saying the FDA raised concerns about CSL’s manufacturing practices. “These are routine inspections the FDA does, and aren’t a final determination of compliance.”

Link to Company News:{3400398Z US <Equity> CN <GO>} Link to Company News:{CSL AU <Equity> CN <GO>}

To contact the reporter on this story: Nichola Saminather in Sydney at

To contact the editor responsible for this story: Iain Wilson at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.